1. Home
  2. GDTC vs AIMD Comparison

GDTC vs AIMD Comparison

Compare GDTC & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CytoMed Therapeutics Limited

GDTC

CytoMed Therapeutics Limited

HOLD

Current Price

$0.88

Market Cap

10.4M

Sector

Health Care

ML Signal

HOLD

Logo Ainos Inc.

AIMD

Ainos Inc.

HOLD

Current Price

$1.43

Market Cap

10.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GDTC
AIMD
Founded
2018
1984
Country
Singapore
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.4M
10.6M
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
GDTC
AIMD
Price
$0.88
$1.43
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
15.7K
23.4K
Earning Date
04-24-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$124,157.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
498.95
52 Week Low
$0.68
$1.26
52 Week High
$3.68
$4.44

Technical Indicators

Market Signals
Indicator
GDTC
AIMD
Relative Strength Index (RSI) 49.10 47.93
Support Level $0.73 $1.33
Resistance Level $1.08 $1.66
Average True Range (ATR) 0.10 0.10
MACD 0.01 0.00
Stochastic Oscillator 54.19 30.30

Price Performance

Historical Comparison
GDTC
AIMD

About GDTC CytoMed Therapeutics Limited

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

About AIMD Ainos Inc.

Ainos Inc is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics. Its primary strategic focus is the commercialization of its proprietary scent digitization platform, AI Nose, while the company also continue to develop therapeutic assets based on its low-dose oral interferon program, VELDONA. Its core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which it refers to as a smell language model (SLM), to digitize scent and volatile organic compound (VOC) signals into Smell ID, a machine-readable data format.

Share on Social Networks: